Marc Damelin

Marc Damelin has a diverse work experience in the biotechnology and pharmaceutical industry. Marc is currently serving as the Vice President, Biology at Mersana Therapeutics, a position they have held since January 2021. Prior to this role, they worked as an Executive Director at Mersana Therapeutics from February 2019 to January 2021 and as a Senior Director from May 2017 to January 2019.

Before joining Mersana Therapeutics, Marc worked at Pfizer for a decade, starting in March 2007. During their time at Pfizer, they held the position of Associate Director and served as a research team leader in oncology drug discovery and development. Marc specialized in antibody-drug conjugates (ADC) and gained clinical experience with three compounds. Additionally, they supervised research team leaders, bench scientists, and postdoctoral fellows.

Marc also has experience in academia, having worked as a Postdoctoral Research Fellow at Columbia University from August 2002 to February 2007. Marc was a Damon Runyon Fellow and focused on stem cells, epigenetics, and DNA methylation under the guidance of Professor Tim Bestor.

In addition to their industry and academic experience, Marc is involved with the Healthcare Businesswomen's Association, where they serve as a mentor. Furthermore, they will be joining mAbs Journal as an Assistant Editor starting in January 2023.

Marc Damelin received a B.S. degree in Physics from Yale University in 1996. Marc then pursued a Ph.D. in Biophysics at Harvard University, completing their studies in 2002.